62411-08-9 Usage
Uses
Used in Pharmaceutical Industry:
(5Z,13E,15S)-15-Methyl-9α,11α,15-trihydroxyprosta-5,13-dien-1-oic acid 1,9-lactone is used as a pharmaceutical agent for its potential role in modulating physiological processes such as inflammation and smooth muscle contraction. Its unique structure and bioactivity make it a promising candidate for the development of new drugs targeting various conditions.
Used in Research Applications:
In the field of scientific research, (5Z,13E,15S)-15-Methyl-9α,11α,15-trihydroxyprosta-5,13-dien-1-oic acid 1,9-lactone serves as a valuable tool for studying the mechanisms of prostaglandin action and their involvement in various physiological processes. Its unique structure allows researchers to investigate the specific interactions and effects of this molecule on cellular and molecular levels, contributing to a better understanding of its potential applications and therapeutic uses.
Check Digit Verification of cas no
The CAS Registry Mumber 62411-08-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,2,4,1 and 1 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 62411-08:
(7*6)+(6*2)+(5*4)+(4*1)+(3*1)+(2*0)+(1*8)=89
89 % 10 = 9
So 62411-08-9 is a valid CAS Registry Number.
InChI:InChI=1/C21H34O4/c1-3-4-9-13-21(2,25)14-12-18-17(19(23)16-20(18)24)11-8-6-5-7-10-15-22/h6,8,12,14-19,23-25H,3-5,7,9-11,13H2,1-2H3/b8-6-,14-12+/t17-,18-,19+,21+/m1/s1
62411-08-9Relevant academic research and scientific papers
Synthesis and Platelet Aggregation Inhibiting Activity of Prostaglandin D Analogues
Bundy, Gordon L.,Morton, D. R.,Peterson, D. C.,Nishizawa, E. E.,Miller, W. L.
, p. 790 - 799 (2007/10/02)
Several prostaglandin D (PGD) analogues have been synthesized, incorpotating the following variations: (a) varying degrees of side-chain unsaturation, (b) C-9 hydroxy removed or in the unnatural 9β configuration, (c) metabolically stabilized analogues (e.
